Crossject franchit une nouvelle étape clé dans la fabrication de ZEPIZURE®
July 18, 2024 01:30 ET
|
CROSSJECT
Fabrication réussie d’un autre Lot Règlementaire de ZEPIZURE® sur le nouveau site de fabricationUne étape importante qui complète les résultats satisfaisants obtenus avec les lots précédents dans le...
Crossject achieves key ZEPIZURE® manufacturing milestone
July 18, 2024 01:30 ET
|
CROSSJECT
Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...
Needle-free vaccine delivery platform aims to end frozen storage needs and improve access
June 06, 2023 04:00 ET
|
aVaxziPen
CEPI to initially provide up to US$1.6 million to aVaxziPen to advance development of needle-free vaccine technology aVaxziPen’s innovative vaccine delivery platform aims to improve access to...
aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress
April 03, 2023 03:00 ET
|
aVaxziPen
OXFORD, United Kingdom, April 03, 2023 (GLOBE NEWSWIRE) -- aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World...
University Hospitals Joins Needle-Free Blood Draw Movement, Adopts PIVO™
July 18, 2018 08:00 ET
|
University Hospitals Cleveland Medical Center
CLEVELAND, July 18, 2018 (GLOBE NEWSWIRE) -- As part of its ongoing commitment to provide high-quality, patient-centered medical care, University Hospitals (UH) today announced that it has...
Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
June 13, 2016 01:18 ET
|
SymBio Pharmaceuticals Ltd
TOKYO, June 13, 2016 (GLOBE NEWSWIRE) -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio”) announced today that the Phase 3 clinical trial on “SyB P-1501” – a drug for...